Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor
US9943596B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 23, 2015 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | Nov 23, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.